FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978258523> ?p ?o ?g. }

• W2978258523 endingPage "S134" @default.
• W2978258523 startingPage "S133" @default.
• W2978258523 abstract "Introduction: Ribavirin (RBV) is known to cause hemolytic anemia that can lead to hyperbilirubinemia. In addition, the NS3/NS4A protease inhibitor ABT-450 can increase unconjugated bilirubin levels due to transporter inhibition. We report the rate of hyperbilirubinemia in HCV genotype 1-infected patients treated with ABT-450/r-ombitasvir (formerly ABT-267) and dasabuvir (formerly ABT-333) (3D regimen) with or without RBV. Methods: Data from 910 patients randomized in 3 phase 3 trials (PEARL-II, PEARL-III, and PEARLIV), which examined the contribution of RBV to the safety and efficacy of the 3D regimen, were used to evaluate the incidence and severity of clinical events related to bilirubin (hyperbilirubinemia, jaundice) during 12 weeks of treatment. Total, direct, and indirect bilirubin were assessed at baseline and every 1-2 weeks per protocol. Results: Total bilirubin elevations of >3X ULN occurred in 23/401 (5.7%) 3D+RBV patients and in 2/509 (0.4%) patients receiving the RBV-free 3D regimen. The majority of patients in each group (>90%) had normal total bilirubin levels at the end of treatment. Mean total bilirubin levels were significantly higher at each treatment visit in the RBV-containing treatment groups. Mean total bilirubin peaked at week 1 in both treatment groups (predominantly indirect), and declined to baseline by week 2 in the RBV-free group. Events of hyperbilirubinemia and jaundice were mostly mild, occurred within the first 2 weeks of treatment and did not result in study drug discontinuation. One patient underwent RBV dose modification and one interrupted study drug due to hyperbilirubinemia; both patients achieved sustained virologic response 12 weeks post-treatment. Two patients receiving 3D+RBV experienced ALT ≥3X ULN and total bilirubin ≥2X ULN, however, the timing and predominance of indirect bilirubin were not consistent with drug induced liver injury. No serious adverse events related to hyperbilirubinemia were reported. Conclusion: Low rates of hyperbilirubinemia were observed with both 3D regiments but were less frequent in the RBV-free 3D regimens, suggesting that increases in bilirubin associated with ABT-450-containing regimens are enhanced by RBV-induced hemolysis. Bilirubin-related adverse events were infrequent with both regimens and did not affect treatment response. Disclosure - D Bernstein - Grant/Research Support: AbbVie, BMS, Gilead, Janssen, Vertex, Merck, Genentech; Consultant/Speaker’s Bureau: AbbVie, Gilead, Janssen, Vertex, Merck. N Tsai - Consultant/Advisory Board: AbbVie, Gilead, Janssen; Grant/Research Support: AbbVie, Janssen, Genentech-Roche, Vertex, BMS; Speaker’s Bureau: Gilead, Genentech-Roche, BMS, Vertex, Merck, Janssen. T Hassanein - Grant/Research Support: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Gilead Sciences, Janssen, Idenix, Ikaria, Mochida, Roche, Ocera, Taigen, Takeda, Salix, Sundise, Vertex. Speaker’s Bureau: Baxter, Bristol-Myers Squibb, Gilead, Salix; Advisory Board: AbbVie, Bristol-Myers Squibb. F Rodriguez-Perez - Advisory Board: AbbVie, Gilead, Janssen, Merck; Speaker’s Bureau: BMS, Merck. M Romero-Gomez - Advisory Board/Speaker’s Bureau: AbbVie, Roche, Gilead Sciences, MSD, Janssen, Merz, BMS, Boehringer Ingelheim, GSK. R Marinho - Advisory Board/Speaker’s Bureau: AbbVie, Gilead, BMS, Roche, Merck, Janssen. R Planas Vila - Advisory Board: Roche, MSD, BMS, Gilead, Janssen; Speaker’s Bureau: Roche, MSD, BMS, Gilead, Janssen, Boehringer Ingelheim; Grant/Research Support: Roche, MSD, BMS, Gilead, Janssen. M Colombo - Grant/Research Support: Merck, Roche, BMS, Gilead; Advisory committee; AbbVie, Merck, Roche, Novartis, Bayer, BMS, Gilead Sciences, Tibotec, Vertex, Janssen Cilag, Achillion, Lundbeck, Abbott, Boehringer Ingelheim, GSK, GenSpera; Speaker’s Bureau: Tibotec, Roche, Novartis, Bayer, BMS, Gilead Sciences, Vertex. M Pedrosa - Employee/Stockholder: AbbVie. S Lovell - Employee/Stockholder: AbbVie. J Enejosa - Employee/Stockholder: AbbVie. Y Luo - Employee/Stockholder: AbbVie. D Cohen - Employee/Stockholder: AbbVie. KR Reddy - Ad-Hoc Advisory Board: AbbVie, BMS, Gilead, Vertex, Janssen, Merck, Genentech-Roche, Idenix; Grant/Research Support: AbbVie, BMS, Gilead, Vertex, Janssen, Merck, Genentech-Roche, Genfit. This research was supported by an industry grant from AbbVie.Table 1" @default.
• W2978258523 created "2019-10-10" @default.
• W2978258523 creator A5003671579 @default.
• W2978258523 creator A5014789709 @default.
• W2978258523 creator A5019176590 @default.
• W2978258523 creator A5039696464 @default.
• W2978258523 creator A5040431440 @default.
• W2978258523 creator A5047871839 @default.
• W2978258523 creator A5058541785 @default.
• W2978258523 creator A5063730756 @default.
• W2978258523 creator A5063864088 @default.
• W2978258523 creator A5064776163 @default.
• W2978258523 creator A5073702849 @default.
• W2978258523 creator A5074748590 @default.
• W2978258523 creator A5079138934 @default.
• W2978258523 creator A5079986926 @default.
• W2978258523 date "2014-10-01" @default.
• W2978258523 modified "2023-10-17" @default.
• W2978258523 title "Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients" @default.
• W2978258523 doi "https://doi.org/10.14309/00000434-201410002-00445" @default.
• W2978258523 hasPublicationYear "2014" @default.
• W2978258523 type Work @default.
• W2978258523 sameAs 2978258523 @default.
• W2978258523 citedByCount "0" @default.
• W2978258523 crossrefType "journal-article" @default.
• W2978258523 hasAuthorship W2978258523A5003671579 @default.
• W2978258523 hasAuthorship W2978258523A5014789709 @default.
• W2978258523 hasAuthorship W2978258523A5019176590 @default.
• W2978258523 hasAuthorship W2978258523A5039696464 @default.
• W2978258523 hasAuthorship W2978258523A5040431440 @default.
• W2978258523 hasAuthorship W2978258523A5047871839 @default.
• W2978258523 hasAuthorship W2978258523A5058541785 @default.
• W2978258523 hasAuthorship W2978258523A5063730756 @default.
• W2978258523 hasAuthorship W2978258523A5063864088 @default.
• W2978258523 hasAuthorship W2978258523A5064776163 @default.
• W2978258523 hasAuthorship W2978258523A5073702849 @default.
• W2978258523 hasAuthorship W2978258523A5074748590 @default.
• W2978258523 hasAuthorship W2978258523A5079138934 @default.
• W2978258523 hasAuthorship W2978258523A5079986926 @default.
• W2978258523 hasConcept C120665830 @default.
• W2978258523 hasConcept C121332964 @default.
• W2978258523 hasConcept C126322002 @default.
• W2978258523 hasConcept C142462285 @default.
• W2978258523 hasConcept C203014093 @default.
• W2978258523 hasConcept C2522874641 @default.
• W2978258523 hasConcept C2776408679 @default.
• W2978258523 hasConcept C2777100407 @default.
• W2978258523 hasConcept C2777513400 @default.
• W2978258523 hasConcept C2778456037 @default.
• W2978258523 hasConcept C2778867932 @default.
• W2978258523 hasConcept C2779298103 @default.
• W2978258523 hasConcept C2780040827 @default.
• W2978258523 hasConcept C2781413609 @default.
• W2978258523 hasConcept C2993143319 @default.
• W2978258523 hasConcept C3013748606 @default.
• W2978258523 hasConcept C61511704 @default.
• W2978258523 hasConcept C71924100 @default.
• W2978258523 hasConcept C90924648 @default.
• W2978258523 hasConceptScore W2978258523C120665830 @default.
• W2978258523 hasConceptScore W2978258523C121332964 @default.
• W2978258523 hasConceptScore W2978258523C126322002 @default.
• W2978258523 hasConceptScore W2978258523C142462285 @default.
• W2978258523 hasConceptScore W2978258523C203014093 @default.
• W2978258523 hasConceptScore W2978258523C2522874641 @default.
• W2978258523 hasConceptScore W2978258523C2776408679 @default.
• W2978258523 hasConceptScore W2978258523C2777100407 @default.
• W2978258523 hasConceptScore W2978258523C2777513400 @default.
• W2978258523 hasConceptScore W2978258523C2778456037 @default.
• W2978258523 hasConceptScore W2978258523C2778867932 @default.
• W2978258523 hasConceptScore W2978258523C2779298103 @default.
• W2978258523 hasConceptScore W2978258523C2780040827 @default.
• W2978258523 hasConceptScore W2978258523C2781413609 @default.
• W2978258523 hasConceptScore W2978258523C2993143319 @default.
• W2978258523 hasConceptScore W2978258523C3013748606 @default.
• W2978258523 hasConceptScore W2978258523C61511704 @default.
• W2978258523 hasConceptScore W2978258523C71924100 @default.
• W2978258523 hasConceptScore W2978258523C90924648 @default.
• W2978258523 hasLocation W29782585231 @default.
• W2978258523 hasOpenAccess W2978258523 @default.
• W2978258523 hasPrimaryLocation W29782585231 @default.
• W2978258523 hasRelatedWork W2399748013 @default.
• W2978258523 hasRelatedWork W2626697548 @default.
• W2978258523 hasRelatedWork W2791436202 @default.
• W2978258523 hasRelatedWork W2792996680 @default.
• W2978258523 hasRelatedWork W2807826472 @default.
• W2978258523 hasRelatedWork W2912781543 @default.
• W2978258523 hasRelatedWork W2913735655 @default.
• W2978258523 hasRelatedWork W3047114976 @default.
• W2978258523 hasRelatedWork W3163875593 @default.
• W2978258523 hasRelatedWork W3171826434 @default.
• W2978258523 hasVolume "109" @default.
• W2978258523 isParatext "false" @default.
• W2978258523 isRetracted "false" @default.
• W2978258523 magId "2978258523" @default.
• W2978258523 workType "article" @default.